BR112021006858A2 - métodos e formulações para tratar náusea e vômito induzidos por quimioterapia - Google Patents

métodos e formulações para tratar náusea e vômito induzidos por quimioterapia Download PDF

Info

Publication number
BR112021006858A2
BR112021006858A2 BR112021006858-9A BR112021006858A BR112021006858A2 BR 112021006858 A2 BR112021006858 A2 BR 112021006858A2 BR 112021006858 A BR112021006858 A BR 112021006858A BR 112021006858 A2 BR112021006858 A2 BR 112021006858A2
Authority
BR
Brazil
Prior art keywords
formulation
day
patient
chemotherapy
fact
Prior art date
Application number
BR112021006858-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Catherine Jacobson
Original Assignee
Tilray Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc. filed Critical Tilray Inc.
Publication of BR112021006858A2 publication Critical patent/BR112021006858A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021006858-9A 2018-10-10 2019-10-10 métodos e formulações para tratar náusea e vômito induzidos por quimioterapia BR112021006858A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10
US62/743,839 2018-10-10
PCT/US2019/055662 WO2020077103A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
BR112021006858A2 true BR112021006858A2 (pt) 2021-07-13

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006858-9A BR112021006858A2 (pt) 2018-10-10 2019-10-10 métodos e formulações para tratar náusea e vômito induzidos por quimioterapia

Country Status (12)

Country Link
US (1) US20200113847A1 (https=)
EP (1) EP3863614A1 (https=)
JP (1) JP2022502471A (https=)
KR (1) KR20210116432A (https=)
AU (1) AU2019357608A1 (https=)
BR (1) BR112021006858A2 (https=)
CA (1) CA3115985A1 (https=)
CL (1) CL2021000882A1 (https=)
CO (1) CO2021005797A2 (https=)
MX (1) MX2021004138A (https=)
PE (1) PE20211198A1 (https=)
WO (1) WO2020077103A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof
CN115968278A (zh) * 2020-05-18 2023-04-14 麦氏生物科技有限公司 脂质-聚合物组合物及使用方法
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤
US20240252464A1 (en) * 2022-07-06 2024-08-01 Avantsar Sdn Bhd A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
JP4994039B2 (ja) * 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
WO2006124698A2 (en) * 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2015068052A2 (en) * 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
CA3025208A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
CA3036585A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US20200163931A1 (en) * 2016-10-12 2020-05-28 Columbia Care Llc Oral composition of extracted cannabinoids and methods of use thereof
US20190336472A1 (en) * 2017-01-03 2019-11-07 Receptor Holdings, Inc. Medicinal compounds and nutritional supplements
EP3582755A4 (en) * 2017-02-15 2020-12-23 Molecular Infusions, LLC PREPARATIONS
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
CA3119786A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
EP3755372A1 (en) * 2018-02-23 2020-12-30 Nicola Michael Spirtos Cannabis based therapeutic and method of use
KR20210055042A (ko) * 2018-07-31 2021-05-14 오스칸 그룹 홀딩스 엘티디 “고체의 자가-유화 약학 조성물”

Also Published As

Publication number Publication date
WO2020077103A1 (en) 2020-04-16
US20200113847A1 (en) 2020-04-16
CA3115985A1 (en) 2020-04-16
JP2022502471A (ja) 2022-01-11
KR20210116432A (ko) 2021-09-27
CL2021000882A1 (es) 2021-08-27
AU2019357608A1 (en) 2021-05-27
MX2021004138A (es) 2021-08-05
PE20211198A1 (es) 2021-07-01
CO2021005797A2 (es) 2021-05-20
EP3863614A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
DK2600850T3 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NOCICEPTIVE PAIN
US11541006B2 (en) Aqueous formulation for insoluble drugs
US11229602B2 (en) Formulations for treating bladder cancer
BR112021006858A2 (pt) métodos e formulações para tratar náusea e vômito induzidos por quimioterapia
ES2498795T3 (es) Composición de liposomas que contienen antihistamínicos y corticosteroides y su uso para la fabricación de un medicamento para tratar la rinitis y trastornos relacionados
JP2022549729A (ja) 酢酸アビラテロンを含む医薬組成物、並びにその製造方法及び使用
BR112020004947A2 (pt) canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos
EP1773294A2 (en) Compositions for delivering highly water soluble drugs
US8263574B2 (en) Topical formulations for the treatment of depression with S adenosyl methionine
WO2022160971A1 (zh) 一种含有难溶性药物的浓缩液以及由其制备的乳剂
Ahmad et al. Development of aqueous based formulation of docetaxel: safety and pharmacokinetics in patients with advanced solid tumors
EP3826615A1 (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
US20180071216A1 (en) Method and composition for treating cystitis
CN101534791B (zh) 含季铵化合物的组合物
TWI786328B (zh) 緩釋眼用藥物組合物及其用途
US20060276436A1 (en) Farnesyl dibenzodiazepinone formulation
CN102920657B (zh) 16-妊娠双烯醇酮亚微乳注射剂及其制备方法
CN113559060B (zh) 蜂胶磷脂复合物的亚微乳剂及其制备方法
CN103405396B (zh) 一种含蓬莪术环二烯的药物组合物及其制药用途
AU2005265998A1 (en) Compositions and methods for smoking cessation
TWI787189B (zh) 用於治療膀胱癌之配方
TW202220668A (zh) 用於疼痛控制之關節內皮質類固醇的藥學組成物
WO2026090749A1 (en) Pharmaceutical formulations comprising aprepitant
HK40018736A (en) Pharmaceutical composition containing abiraterone acetate and preparation method and use thereof
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements